JP2009511485A5 - - Google Patents

Download PDF

Info

Publication number
JP2009511485A5
JP2009511485A5 JP2008534672A JP2008534672A JP2009511485A5 JP 2009511485 A5 JP2009511485 A5 JP 2009511485A5 JP 2008534672 A JP2008534672 A JP 2008534672A JP 2008534672 A JP2008534672 A JP 2008534672A JP 2009511485 A5 JP2009511485 A5 JP 2009511485A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008534672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511485A (ja
JP5140595B2 (ja
Filing date
Publication date
Priority claimed from US11/524,683 external-priority patent/US8137677B2/en
Application filed filed Critical
Publication of JP2009511485A publication Critical patent/JP2009511485A/ja
Publication of JP2009511485A5 publication Critical patent/JP2009511485A5/ja
Application granted granted Critical
Publication of JP5140595B2 publication Critical patent/JP5140595B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008534672A 2005-10-06 2006-10-04 非タンパク質安定化クロストリジウム毒素医薬組成物 Expired - Fee Related JP5140595B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72512605P 2005-10-06 2005-10-06
US60/725,126 2005-10-06
US11/524,683 US8137677B2 (en) 2005-10-06 2006-09-21 Non-protein stabilized clostridial toxin pharmaceutical compositions
US11/524,683 2006-09-21
PCT/US2006/038913 WO2007041664A1 (en) 2005-10-06 2006-10-04 Non-protein stabilized clostridial toxin pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012162277A Division JP5758856B2 (ja) 2005-10-06 2012-07-23 非タンパク質安定化クロストリジウム毒素医薬組成物

Publications (3)

Publication Number Publication Date
JP2009511485A JP2009511485A (ja) 2009-03-19
JP2009511485A5 true JP2009511485A5 (https=) 2009-11-26
JP5140595B2 JP5140595B2 (ja) 2013-02-06

Family

ID=37527018

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008534672A Expired - Fee Related JP5140595B2 (ja) 2005-10-06 2006-10-04 非タンパク質安定化クロストリジウム毒素医薬組成物
JP2012162277A Expired - Fee Related JP5758856B2 (ja) 2005-10-06 2012-07-23 非タンパク質安定化クロストリジウム毒素医薬組成物
JP2014075596A Pending JP2014139229A (ja) 2005-10-06 2014-04-01 非タンパク質安定化クロストリジウム毒素医薬組成物
JP2017010322A Expired - Fee Related JP6235176B2 (ja) 2005-10-06 2017-01-24 非タンパク質安定化クロストリジウム毒素医薬組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012162277A Expired - Fee Related JP5758856B2 (ja) 2005-10-06 2012-07-23 非タンパク質安定化クロストリジウム毒素医薬組成物
JP2014075596A Pending JP2014139229A (ja) 2005-10-06 2014-04-01 非タンパク質安定化クロストリジウム毒素医薬組成物
JP2017010322A Expired - Fee Related JP6235176B2 (ja) 2005-10-06 2017-01-24 非タンパク質安定化クロストリジウム毒素医薬組成物

Country Status (16)

Country Link
US (5) US8137677B2 (https=)
EP (2) EP1931306B2 (https=)
JP (4) JP5140595B2 (https=)
KR (1) KR101314952B1 (https=)
AU (1) AU2006299366B2 (https=)
CA (1) CA2602926C (https=)
CY (1) CY1117727T1 (https=)
DK (1) DK2679217T3 (https=)
ES (1) ES2580010T3 (https=)
HU (1) HUE027810T2 (https=)
MX (1) MX2007012062A (https=)
NZ (1) NZ562033A (https=)
PL (1) PL2679217T3 (https=)
PT (1) PT2679217T (https=)
SI (1) SI2679217T1 (https=)
WO (1) WO2007041664A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
BRPI0513850A (pt) * 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
SG160357A1 (en) * 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
BRPI0613631A8 (pt) 2005-07-18 2017-12-26 Univ Massachusetts Lowell nanoemulsão e método,
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
BRPI0619134B8 (pt) 2005-12-01 2021-05-25 Univ Massachusetts Lowell nanoemulsão, composição farmacêutica, composição, métodos cosméticos para o tratamento de rugas, linhas faciais e/ou linhas do pescoço, e de retardar o início das rugas, linhas faciais e/ou linhas do pescoço, e, método de fabricação de uma nanoemulsão
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
SG10201607909WA (en) 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
US8617568B2 (en) 2007-07-10 2013-12-31 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
HUE037932T2 (hu) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR20110106346A (ko) 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
AU2009332947C1 (en) 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
CA2766649C (en) 2009-06-24 2016-08-23 Charles N.S. Soparkar Zinc supplementation to increase responsiveness to metalloprotease therapy
EP2445521A4 (en) 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
US11152669B2 (en) * 2009-11-09 2021-10-19 Enerdel, Inc. Scalable battery module
JP5990176B2 (ja) * 2010-10-12 2016-09-07 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
WO2012134240A2 (ko) * 2011-03-31 2012-10-04 (주)메디톡스 보툴리눔 독소의 동결건조제제
KR20140147950A (ko) * 2013-06-20 2014-12-31 서울대학교산학협력단 필러와 보틀리눔 독소를 포함하는 피부 주름, 노화 개선 또는 신경근육 관련 질환 치료용 조성물
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
KR102525493B1 (ko) 2014-07-07 2023-04-25 라이프래프트 바이오사이언시즈 인코포레이티드 장기 순환 물질이 없는 폴록사머 조성물 및 이의 제조 방법 및 용도
CN107106780B (zh) 2014-12-23 2020-10-16 莫茨制药有限及两合公司 肉毒杆菌毒素预填充式容器
WO2017179775A1 (en) * 2016-04-12 2017-10-19 Hugel Inc. Microstructure formulation techniques for botulinum toxin
BR112019004935A2 (pt) * 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
EP3470054B1 (en) * 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US20190185837A1 (en) 2017-12-20 2019-06-20 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for treatments of fibrosis associated disorders
CA3112394A1 (en) * 2018-09-13 2020-03-19 Allergan, Inc. Clostridial toxin - hyaluronic acid compositions

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE68524T1 (de) * 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
DE3603444A1 (de) * 1986-02-05 1987-08-06 Thomae Gmbh Dr K Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
CA2138020C (en) * 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
DE69627963T2 (de) * 1995-06-06 2004-03-04 Pearce, L. Bruce, Cambridge Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
JPH0952844A (ja) * 1995-08-10 1997-02-25 Amano Pharmaceut Co Ltd 酵素含有内服液剤
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
CN1073626C (zh) 1997-10-18 2001-10-24 卫生部兰州生物制品研究所 A型肉毒结晶毒素的生产工艺及生产该毒素所需的冻干保护液
AU2340299A (en) * 1998-01-26 1999-08-09 University Of Massachusetts Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
IL126182A0 (en) 1998-09-11 1999-05-09 Nun Yehoshua Ben Cryosurgical instrument
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US20050147690A1 (en) * 1998-09-25 2005-07-07 Masters David B. Biocompatible protein particles, particle devices and methods thereof
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
ATE519494T1 (de) 2000-02-08 2011-08-15 Allergan Inc Pharmazeutische zusammensetzungen mit botulinum- toxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6653062B1 (en) * 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
PT1517698E (pt) * 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
US20040143213A1 (en) * 2002-11-12 2004-07-22 Collegium Pharmaceutical, Inc. Inertial drug delivery system
US20060002862A1 (en) * 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
CA2510058C (en) 2002-12-20 2010-03-16 Botulinum Toxin Research Associates, Inc. Improved pharmaceutical botulinum toxin compositions
WO2004093870A1 (en) * 2003-03-20 2004-11-04 Pharmacia Corporation Treatment and prevention of otic disorders
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
EP1660013A4 (en) * 2003-08-26 2011-07-20 Gel Del Technologies Inc BIOMATERIAL AND PROTEIN BIOCOACERVATES, METHODS OF MAKING AND USING THEM
EP1691746B1 (en) * 2003-12-08 2015-05-27 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
US20050214325A1 (en) * 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
CN101001613B (zh) * 2004-06-28 2010-09-29 生命周期药物公司 作为液体制剂载体的多孔片剂
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
BRPI0513850A (pt) * 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
PL1776137T3 (pl) * 2004-08-04 2015-03-31 Ipsen Biopharm Ltd Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US9504658B2 (en) * 2004-11-09 2016-11-29 Board Of Regents, The University Of Texas System Stabilized HME composition with small drug particles
PT1954308E (pt) * 2005-09-16 2011-11-03 Merial Ltd Estabilizadores para vacinas liofilizadas
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
CA2681567C (en) * 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
EP1985276A1 (en) * 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
ES2732150T3 (es) * 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
JP5990176B2 (ja) * 2010-10-12 2016-09-07 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤

Similar Documents

Publication Publication Date Title
JP2008543290A5 (https=)
JP2008543728A5 (https=)
JP2009511485A5 (https=)
JP2008543729A5 (https=)
JP2009543688A5 (https=)
JP2009538387A5 (https=)
JP2009525726A5 (https=)
JP2009542573A5 (https=)
JP2009507826A5 (https=)
JP2006257115A5 (https=)
JP2009506999A5 (https=)
JP2009520703A5 (https=)
JP2008533230A5 (https=)
JP2007231207A5 (https=)
JP2010530463A5 (https=)
JP2009503140A5 (https=)
JP2006063441A5 (https=)
JP2008543830A5 (https=)
JP2006045672A5 (https=)
JP2007321035A5 (https=)
JP2008538930A5 (https=)
JP2009062402A5 (https=)
JP2009526126A5 (https=)
JP2007246653A5 (https=)
JP2007190226A5 (https=)